RxDoctor Payments Data

Monita Yuen-Green, MD

Internal Medicine · Ukiah, CANPI 1013000868

Payments from drug & device makers

$2,296in general payments, 2019–2025

Across 104 payments — averaging $22.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$359
  • Lilly USA, LLC$277
  • Boehringer Ingelheim$182
  • Gilead$177
  • GSK$168
  • Johnson & Johnson$161
  • plus $972 from 14 others

What the payments were for

  • Food & beverage$2,27499%
  • Education$221%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,296 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$111,877
Medicare patients
171
Services billed
808

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin32$50,677
EliquisApixaban40$40,069
OzempicSemaglutide18$23,925
JanuviaSitagliptin Phosphate12$17,405
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$12,059
XareltoRivaroxaban11$10,097
Breo ElliptaFluticasone/Vilanterol16$6,919
Pregabalin25$5,690
MyrbetriqMirabegron11$5,082
SynthroidLevothyroxine Sodium52$3,001
Amlodipine Besylate318$2,546
Celecoxib59$2,189
Rosuvastatin Calcium141$2,044
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen114$1,970
Losartan Potassium212$1,909

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$182$50,67732 claims
PfizerEliquis$359$40,06940 claims
Novo NordiskOzempic$136$23,92518 claims
GSKTrelegy Ellipta, Breo Ellipta$168$18,97930 claims
MerckJanuvia$113$17,40512 claims
Johnson & JohnsonXarelto$161$10,09711 claims
Astellas Pharma US IncMyrbetriq$44$5,08211 claims
AbbVieSynthroid$155$3,00152 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Ukiah

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →